Mazdutide (R&D Code: LY3305677) is a novel, long-acting, single-molecule dual agonist co-developed by Innovent Biologics and Eli Lilly. It uniquely targets and activates two key metabolic hormone receptors simultaneously:
1.Glucagon-like peptide-1 receptor (GLP-1R): Primarily known for stimulating insulin secretion (lowering blood sugar), slowing gastric emptying (promoting satiety), and reducing appetite.
2.Glucagon receptor (GCGR): Primarily known for stimulating hepatic glucose production (raising blood sugar during fasting) and promoting lipolysis (fat breakdown). It also increases energy expenditure.
This dual agonism creates a complex, integrated metabolic effect distinct from pure GLP-1 agonists like Semaglutide (Ozempic/Wegovy) or Tirzepatide (Mounjaro/Zepbound - a GLP-1/GIP dual agonist).
